$KIN News

Last published 4y ago

4y agoELAN PRTS TSPQ KINTCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of DirectorsBusiness WireTCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April
5y agoDCRC KIN ROCR SVOKMoore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law FirmPR NewswireNEW YORK, June 22, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
5y agoCCL NCLH GM LZB+12Stocks making the biggest moves midday: GM, H&R Block, Citigroup and moreCNBCThese are the stocks posting the largest moves in midday trading.
5y agoAUVI KIN RKDA SNDL+1Thinking about buying stock in Kindred Biosciences, Applied UV, Sundial Growers, Vista Gold, or Arcadia Biosciences?PR NewswireNEW YORK, June 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KIN, AUVI, SNDL, VGZ, and RKDA. To
5y agoORCL RBLX KIN ELAN+12Stocks making the biggest moves in the premarket: Oracle, Roblox, Kindred Biosciences & moreCNBCThe stocks making the biggest moves in premarket trading include Oracle, Roblox, Kindred Biosciences, and more.
5y agoELAN KINElanco Announces Agreement to Acquire Kindred BiosciencesPR NewswireGREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) and Kindred Biosciences, Inc. ((KindredBio, NASDAQ:KIN) today announced the parties have entered into a definitive agreement for Elanco to ac
5y agoELAN KINElanco Announces Agreement to Acquire Kindred BiosciencesBusiness WireBolt-on Acquisition Accelerates Elanco's Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share
5y agoELAN KINKindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by ParvovirusPR NewswireSAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infect
5y agoKINKindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XIPR NewswireSAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtual Jaws & Paws Conference on June 2 and the LD Micro I
5y agoKINKindred Biosciences Announces First Quarter 2021 Financial ResultsPR NewswireSAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided
5y agoKINKindred Biosciences, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 11, 2021 / Kindred Biosciences, Inc. (NASDAQ:KIN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 4:30 PM Eastern Time. To listen to the event live or acce
5y agoKINKindred Biosciences to Announce First Quarter 2021 Financial ResultsPR NewswireSAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 financial results on May 11, 2021, after the market clo
5y agoELAN KINKindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy IndicationPR NewswireSAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the United States Department of Agriculture (USDA) Center for Vete
5y agoKIN PRTS TSPQ TSPQ.UTCW Special Purpose Acquisition Corp. Announces Appointment of Nanxi Liu to Advisory BoardBusiness WireTCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO o
5y agoKINKindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK StudyPR NewswireSAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody progr
5y agoKINKindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial...
5y agoKINKindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth...
5y agoKINKindred Biosciences to Present at Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences ConferencePR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Barclays...
5y agoKINKindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic IndicationPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has...
5y agoKINKindred Biosciences to Present at the BofA Securities Animal Health Virtual SummitPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA...
5y agoKINKindred Biosciences Announces Two New Appointments to Board of DirectorsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has...
5y agoKINKindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic DermatitisPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has...
5y agoKINKindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel DiseasePR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive...
5y agoKIN ELANKindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal AntibodyPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement...
5y agoELAN KINElanco Announces Agreement with KindredBio to Bring First-of-its-Kind Canine Parvovirus Therapy to MarketBusiness WireGREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus (CPV). This deadly disease impacts at least 250,000 puppies annually in the U.S., according ...
5y agoKINKindred Biosciences to Present at Guggenheim Animal Health SummitPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr....
6y agoKINKindred Biosciences to Participate in Stifel Virtual Healthcare Conference and A.G.P. Virtual Healthcare SymposiumPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel...
6y agoKINKindred Biosciences Announces Third Quarter 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial...
6y agoKINKindred Biosciences to Announce Third Quarter 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its third...
6y agoKIN VXRTCentaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine CandidatesPR NewswireCentaur Biopharmaceutical Services Inc. (Centaur), a wholly-owned subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), today announced...
6y agoKIN VXRTKindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine CandidatesPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with...
6y agoKINKindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal AntibodyPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive...
6y agoKINKindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth ConferencePR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C....
6y agoKINKindred Biosciences, Inc.'s (KIN) CEO Richard Chin on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoKINKindred Biosciences Announces Second Quarter 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial...
6y agoKINKindred Biosciences to Announce Second Quarter 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its second...
6y agoKINKindred Biosciences Announces Plan to Strengthen its Strategic PositionPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a plan to...
6y agoKIN VXRTKindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with VaxartPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement...
6y agoKINKindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws ConferencePR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel...
6y agoKINKindred Biosciences Announces First Quarter 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial...
6y agoKINKindred Biosciences to Announce First Quarter 2020 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first...
6y agoKINKindred Biosciences Announces Completion of Mirataz® (mirtazapine transdermal ointment) TransactionPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has...
6y agoKINNew patent granted for: Stimulation of Appetite and Treatment of Anorexia in Dogs and CatsUS Patent Applications (USPTO)
6y agoKINKindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in DogsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive...
6y agoKINKindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial ResultsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has...
6y agoKINKindred Biosciences to Present at Bank of America Merrill Lynch Animal Health SummitPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present ...
6y agoKINNew patent application published for: Il4/Il13 Receptor Molecule for Veterinary UseUS Patent Applications (USPTO)( 1 of 1 )
6y agoKINKindred Biosciences Announces Half-Life Extension Technology for Canine AntibodiesPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today...
6y agoKINKindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in DogsPR NewswireKindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today...
6y agoKINKindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight LossPR NewswireKindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today...